Clinical trials





Current Clinical Trials



Cohort trials



Congenital extrahepatic portosystemic shunts (Abernethy malformation): European Survey of current management strategies and clinical outcome.

923/16 - Pro-Euro DILI Registry - Creation of a Multicentre and Multidisciplinary European Registry of Prospective Drug-Induced Liver Injury Cases (Pro-Euro-DILI).



Liver Cancer



LILLY (REACH 2) : I4T-MC-JVDE: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib” (Lilly).



Bristol-Myers Squibb Clinical Trial Agreement BMS CA209-459: A randomized, multi-center Phase Ill Study of Nivolumab versus Sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (CheckMate 459).

0347/18 1898 HCC Cohort: Cohort Study with patients suffering from hepatocellular carcinoma.
275/17 3534 Blueprint HCC: BLU-554-1101 A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with HCC.
1760/18 3805 Axl S: sAxl as Diagnostic Biomarker of Steatosis- and Hepatitis Virus-Induced Hepatocellular Carcinoma.
1585/18 3916 CEUS: Contrast-enhanced ultrasound for the assessment of focal liver lesions in patients with cirrhosis or other risk factors for a Hepatocellular Carcinoma (HCC).
0400/19 4053 MK3475-937: A Phase 3 Double-blinded, Twoarm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937).
2392/18 4003 Cosmic(Exelixis) (OASIS): XL184-312, a randomized, controlled phase 3 study of Cabozantinib (XL184) in combination with Atezolizumab versus Sorafenib in patients with advanced HCC who have not received previous systemic anticancer therapy.



Viral Hepatitis



HBV Cohort. Swiss Hepatitis B Cohort Study. SASL 37.



Abbvie M14-423: A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II).

0727/18 3715 DAA  and Cancer: Effect of Direct Acting Antiviral Drugs on the Occurrence and Recurrence of intra- and extrahepatic Malignancies in Patients with Chronic Hepatitis C.
- - CMV T-Track.

Metabolic Liver Diseases



Intercept 747-303 NASH (REGENERATE): A phase 3, double-blind, randomized, long-term, placebo-controlled, multicenter study evaluating the safety and efficacy of obeticholic acid in subjects with nonalcoholic steatohepatitis NASH.



GENFIT: Resolve-it: Genfit GFT505 in NASH phase 3: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of elafibranor in patients with non-alcoholic steatohepatitis NASH and Fibrosis (Emricasan).

0294/18 3662 Litmus - The European NAFLD Registry Liver Investigation: Testing Marker Utility in Steatohepatitis.
0609/19 4067 Litmus sub-study imaging: Litmus Sub-Study Imaging: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment and Validation of Imaging Modality Performance across the NAFLD Spectrum in a Prospectively Recruited Cohort.
0980/19 4102 NUT-3/NAS (Falk GmbH): Double-blind, randomised, placebo-controlled, phase IIb trial on the efficacy and safety of norursodeoxycholic acid tablets in patients with non-alcoholic steatohepatitis (NASH).
0898/17 3942 Aurora (Tobira) Allergan : A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (TOBIRA).




0548/17 3352 GS-US-384-1944 Cirrhosis on NASH: A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of Selonsertib in subjects with compensated cirrhosis due to nonalcoholic steatohepatitis, Stellar-4.
- - NABEL Cirhosis Data Bank (Canada and Bern).
198/15 2854

Prosper: Phase IV observational hepatic encephalopathy +/- rifaximin.



Vascular Liver Diseases



Valdig Consortium for the promotion of the study of vacular liver diseases.



Autoimmune Liver Diseases

366/15 3004 Intercept 747-302 Cobalt: A Phase 3b, double-blind, randomized, placebo-controlled, multicenter study evaluating the effect of obeticholic acid on clinical outcomes in subjects with primary biliary cirrhosis.



SASL 38: Swiss Registry on Autoimmune Hepatitis.



SASL 39: Swiss Registry on Primary Biliary Cholangitis.

2236/16 3320 SASL 40: Swiss cohort on Primary Sclerosing Cholangitis SWISS PSC.
1508/18 - SASL 43: IgG4 Swiss Cohort. Swiss IgG4-Related Hepato-Biliary Disease Cohort Study.
1918/18 3952 NUC-5-PSC (Navitas) Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary slerosing cholangitis.
1968/17 3597 Novartis CVAY736B2201. A two-part randomized, double-blind, placebo-controlled multicenter dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete response to or intolerance of standard therapy (AMBER).




1253/18 3720 The Constans Study: A multi-center, multinational survey of NAFLD-related hospital visits: prevalence, severity, patterns of clinical practive and health-care costs. (Consultations for steatohepatitis).



Investigation of liver involvement in patients with Alpha1-Antitrypsin Deficiency.

487/18 - Combination of non-invasive Tests in chronic liver disease to improve a stage-targeted risk stratification and outcome prediction.



Closed Studies